Amedisys Stock Performance
| AMED Stock | USD 97.46 0.01 0.01% |
Amedisys has a performance score of 10 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Amedisys' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amedisys is expected to be smaller as well. Amedisys right now shows a risk of 0.65%. Please confirm Amedisys treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to decide if Amedisys will be following its price patterns.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Amedisys are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical and fundamental indicators, Amedisys is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.01) | Five Day Return 0.0205 | Year To Date Return 7.22 | Ten Year Return 123.79 | All Time Return 1.8 K |
Last Split Factor 4:3 | Last Split Date 2006-12-05 |
1 | Amedisys Tops Q1 Earnings Estimates | 04/23/2025 |
2 | Acquisition by Perkins Bruce D of 1690 shares of Amedisys subject to Rule 16b-3 | 05/02/2025 |
3 | Amedisys edges lower amid report DOJ initially rejects remedy in UnitedHealth | 05/12/2025 |
4 | Acquisition by Scott Ginn of 8627 shares of Amedisys at 91.77 subject to Rule 16b-3 | 05/23/2025 |
5 | Amedisys, Inc. Receives Consensus Rating of Hold from Analysts | 05/29/2025 |
6 | Disposition of 171 shares by Allyson Guidroz of Amedisys at 94.07 subject to Rule 16b-3 | 05/30/2025 |
7 | Rakuten Medicals Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding | 06/04/2025 |
8 | BrightSpring Soars to All-Time High on Quality Strength Still a Buy | 06/10/2025 |
9 | Heres Why You Should Retain AMED Stock in Your Portfolio for Now | 06/13/2025 |
10 | Can Amedisys, Inc. Performance Keep Up Given Its Mixed Bag Of Fundamentals | 06/25/2025 |
11 | Disposition of 2327 shares by Scott Ginn of Amedisys at 98.03 subject to Rule 16b-3 | 06/26/2025 |
12 | RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development | 06/30/2025 |
13 | Medicare Payment Cuts Threaten UnitedHealths Amedisys Acquisition | 07/01/2025 |
| Begin Period Cash Flow | 138.9 M | |
| Total Cashflows From Investing Activities | -8.4 M |
Amedisys Relative Risk vs. Return Landscape
If you would invest 9,243 in Amedisys on April 22, 2025 and sell it today you would earn a total of 503.00 from holding Amedisys or generate 5.44% return on investment over 90 days. Amedisys is currently generating 0.0876% in daily expected returns and assumes 0.6488% risk (volatility on return distribution) over the 90 days horizon. In different words, 5% of stocks are less volatile than Amedisys, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amedisys Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amedisys' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amedisys, and traders can use it to determine the average amount a Amedisys' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.135
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | AMED | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 0.65 actual daily | 5 95% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Amedisys is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amedisys by adding it to a well-diversified portfolio.
Amedisys Fundamentals Growth
Amedisys Stock prices reflect investors' perceptions of the future prospects and financial health of Amedisys, and Amedisys fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amedisys Stock performance.
| Return On Equity | 0.0715 | ||||
| Return On Asset | 0.0636 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 3.37 B | ||||
| Shares Outstanding | 32.82 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 1.35 X | ||||
| Revenue | 2.35 B | ||||
| Gross Profit | 1.03 B | ||||
| EBITDA | 73.45 M | ||||
| Net Income | 38.16 M | ||||
| Cash And Equivalents | 17.96 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 460.18 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 36.55 X | ||||
| Cash Flow From Operations | 221.66 M | ||||
| Earnings Per Share | 2.71 X | ||||
| Market Capitalization | 3.2 B | ||||
| Total Asset | 2.14 B | ||||
| Retained Earnings | 791.16 M | ||||
| Working Capital | 117.69 M | ||||
| Current Asset | 175.26 M | ||||
| Current Liabilities | 175.19 M | ||||
About Amedisys Performance
By analyzing Amedisys' fundamental ratios, stakeholders can gain valuable insights into Amedisys' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amedisys has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amedisys has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 6.57 | 6.30 | |
| Return On Tangible Assets | 0.05 | 0.06 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.02 | 0.01 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about Amedisys performance evaluation
Checking the ongoing alerts about Amedisys for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amedisys help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Medicare Payment Cuts Threaten UnitedHealths Amedisys Acquisition |
- Analyzing Amedisys' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amedisys' stock is overvalued or undervalued compared to its peers.
- Examining Amedisys' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amedisys' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amedisys' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amedisys' stock. These opinions can provide insight into Amedisys' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |